Sprout Pharmaceuticals

Reuters reported after Monday's market close that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plans on cutting its sales force for Addyi, a treatment aimed at female sexual dysfunction. Reuters noted that an outside sales force handles sales for Addyi, which fell under Valeant's corporate...